Faculty Collaboration Database

Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant 2023 Aug;58(8):953-955

Date

05/07/2023

Pubmed ID

37149674

Pubmed Central ID

PMC10555486

DOI

10.1038/s41409-023-02004-5

Scopus ID

2-s2.0-85158126520 (requires institutional sign-in at Scopus site)

Author List

Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A

Authors

Ruta Brazauskas PhD Associate Professor in the Institute for Health and Equity department at Medical College of Wisconsin
Anita D'Souza MD Associate Professor in the Medicine department at Medical College of Wisconsin
Jing Dong PhD Assistant Professor in the Medicine department at Medical College of Wisconsin
Michael B. Dwinell PhD Director, Professor in the Microbiology and Immunology department at Medical College of Wisconsin
Siegfried Janz MD Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin
Bi Qing Teng Biostatistician II in the Institute for Health and Equity department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Bortezomib
Chemokine CXCL10
Hematopoietic Stem Cell Transplantation
Humans
Maintenance Chemotherapy
Multiple Myeloma
Thalidomide
Transplantation, Autologous